Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1992-09-14
1996-06-25
Dees, Jose G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
549 30, 549 35, 549 36, 549 37, 549 38, 544145, 546206, C07D33902
Patent
active
055301410
ABSTRACT:
2,4-Diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase.
A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4539332 (1985-09-01), Biftu et al.
patent: 4757084 (1988-07-01), Biftu et al.
patent: 4910206 (1990-03-01), Houlihan
patent: 4916145 (1990-04-01), Tilley et al.
patent: 4959361 (1990-09-01), Walser
patent: 4987132 (1991-01-01), Mase et al.
patent: 4992428 (1991-02-01), Houlihan et al.
patent: 4996203 (1991-02-01), Biftu et al.
patent: 5001123 (1991-03-01), Biftu et al.
Biftu, T. et al., "Confirmation and Activity of Tetrahydrofuran Lignans and Analogues as Specific Platelet Activating Factor Antagonists," J. Med. Chem. vol. 29, No. 10 (1986) pp. 1917-1921.
Corey, E. J. et al., "Dual Binding Modes to the Receptor for Platelet Activating Factor (PAF) of Anti-PAF Trans-2,5-Diarylfurans," Tetrahedron Letters, vol. 29, No. 24 (1988) pp. 2899-2902.
Ponpipom, M. M., et al., "(.+-.)-Trans-2-[3-Methylsulfonyl)-4-Propoxyphenyl)-5-(3,4,5-Trimethoxyphe nyl)Tetrahydrofuran (L-659,989), A Novel, Potent PAF Receptor Antagonist," Biochemical and Biophysical Research Communications, vol. 150, No. 3 (1988) pp. 1213-1220.
Musser, J. H., et al., "5-Lipoxygenase: Properties, Pharmacology, and the Quinolinyl(bridge)aryl and Class of Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. pp. 2502-2524.
Guthrie, R. W., et al., "Propenyl Carboxamide Derivatives As Antagonists of Platelet Activating Factor," J. Med. Chem. vol. 33 (1990) pp. 2856-2864.
Graham, D. W., et al., "1,3-Diarylcyclopentanes: A New Class of Potent PAF Receptor Antagonists," MEDI, 1989.
Bartroli, J. J. Med. Chem., vol. 34 (1991) pp. 3328-3334.
Carlcellar, E., et al., J. Med. Chem., vol. 35 (1992) pp. 676-683.
Crawley, G. C., "Methoxytetrahydropyrans, A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2600-2609.
Lave, D., et al., "Pyrrolo(1,2-c)Thiazole Derivatives: Potent PAF Receptor Antagonists," Drugs of the Future, vol. 14, No. 9 (1989) pp. 891-898.
Ogiso, A., et al., "The Structure of Futoenone, A Novel Spiro-Cyclohexedienone Derivative," Tetrahedron Letters, No. 16, (1968) pp. 2003-2008.
Ogiso, A., et al., "The Structure and Total Synthesis of Futoenone, a Constitute of Piper futokadzura SIEB, et ZUCC"., Chem. Pharm. Bull., vol. 18, No. 1, (1970) pp. 105-114.
Ponpipom, M. M., et al., "Structure-Activity Relationships of Kadsurenone Analogues," J. Med. Chem., vol. 30 (1987) pp. 136-142.
Shen, T. Y., "Characterization of a Platelet-Activating Factor Receptor Antagonist Isolated from Halifenteng (Piper futokadsura): Specific Inhibition of in vivo and in vivo Platelet-Activating Factor-Induced Effects," Proc. Natl. Acad. Sci. USA, vol. 82, (Feb. 1985) pp. 672-676.
Weber, K. H., et al., "Hetrazepines as Antagonists of Platelet Activating Factor," Medicinal Research Reviews, vol. 9, No. 1 (Jan.-Mar. 1989) pp. 181-218.
Feinmark, S. J., "Leukotriene C.sub.4 Biosynthesis during Polymorphonuclear Leukocyte-Vascular Cell Interactions," Methods in Enzymology, vol. 187, pp. 559-560, 1990.
Hwang, S., "Specific Receptors of Platelet-Activating Factor, Receptor Heterogeneity, and Signal Transduction Mechanisms," J. Lipid Mediators, vol. 2 (1990) pp. 123-158.
McColl, S. R., "Determination of 5-Lipoxygenase Activity in Human Polymorphonuclear Leukocytes Using High-Performance Liquid Chromatography," J. Chromatography, vol. 378 (1986) pp. 44-449.
O'Donnell, M., et al., "Comparison of the Pulmonary Pharmacology of Lukotrienes and PAF: Effects of their Antagonists," Therapeutic Approaches to Inflammatory Diseases Proceedings of the Fourth International Conference of the Inflammatory Research Association, Oct. 23-27, 1988, White Haven, Pennsylvania, p. 169.
Page, C., et al., "PAF: New Antagonists New Roles in Diseases and a Major Role in Reproductive Biology," 3rd International Conference on Platelet-Activating Factor and Structurally Related Alkyl Ether Lipids, Tokyo, Japan, May 8-12, 1989.
Shen, T. Y., et al., "The Chemical and Biological Propertie of PAF Agonists, Antagonists, and Biosynthetic Inhibitors," Platelet-Activating Factor and Related Mediators, Plenum Press, New York, NY, pp. 153-190, 1989.
Goldstein David M.
Shen T. Y.
Barts Samuel
Center For Innovative Technology
Dees Jos,e G.
Zalesky Cheryl K.
LandOfFree
2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diary does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diary, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diary will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2190112